Bolstered by private capital, modern healthcare marketing firms have looked to fill out service offerings in order to acquire market share. Their next big target could be real-world data expertise. Since bursting onto the pharma services scene several years back, private equity firms have catalyzed a new cohort of commercialization platforms, whose agency acquisition binges and remonetization deals have enabled scale. During this highly acquisitive period, their most sought-after subsegment has probably been the market access agency. With most of the payer-oriented shops accounted for — either having been scooped up by a PE-backed entity or one of the traditional strategics — RWD is emerging as a critical piece as the commercialization platforms seek to come to market in a more competitive way.
Read the full article: Does Private Equity Have a Real-World Data Strategy? //